The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation
- 1 September 1997
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 328 (1) , 61-64
- https://doi.org/10.1016/s0014-2999(97)83028-2
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Rizatriptan vs Sumatriptan in the Acute Treatment of MigraineArchives of Neurology, 1996
- The in vivo pharmacological profile of a 5‐HT1 receptor agonist, CP‐122, 288, a selective inhibitor of neurogenic inflammationBritish Journal of Pharmacology, 1995
- Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene‐related peptideBritish Journal of Pharmacology, 1995
- Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of ratsNeuropharmacology, 1995
- Neuropeptides in Migraine and Cluster HeadacheCephalalgia, 1994
- The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and catsAnnals of Neurology, 1993
- Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraineTrends in Pharmacological Sciences, 1992
- Mode of action of the anti-migraine drug sumatriptanTrends in Pharmacological Sciences, 1991
- EXPERIMENTAL STUDIES ON HEADACHEArchives of Surgery, 1940